HDAC3 and prostate cancer: As expected, AKT phosphorylation was elevated by PTEN knockdown in PTEN‐positive 22Rv1 prostate cancer cells, but PTEN loss‐enhanced AKT phosphorylation was mitigated by HDAC3 co‐knockdown (Fig 6A).